English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduWren Laboratories announced executive leadership for commercial operations and market expansion. Dr. Abdel Halim is appointed CEO and CSO. Troy Tremaine Appointed to CCO, Dr. Eva Szarek Head of Marketing, and Melissa Ferone director of quality. Expansion includes AI-driven mRNA liquid biopsy genomic assays for biopharma and diagnostics.
Tag: Liquid Biopsy for Cancer
New urine-based test detects high-grade prostate cancer, helping men avoid unnecessary biopsies
Researchers at the University of Michigan Rogel Cancer Center have developed a new urine-based test that addresses a major problem in prostate cancer: how to separate the slow-growing form of the disease unlikely to cause harm from more aggressive cancer that needs immediate treatment.
Yale Cancer Center Experts, Scientists to Share Vision and Research at Leading Conference
The five-day session (April 5-10), themed as “Inspiring Science. Fueling Progress. Revolutionizing Care,” will include new findings from Yale Cancer Center researchers.
Liquid biopsies can rapidly detect residual disease following cervical chemoradiation, study finds
Two liquid biopsy tests that look for the presence of human papillomavirus (HPV) in the blood accurately identified patients with a high risk of cervical cancer recurrence after the completion of chemoradiation, a new study confirms.
Children’s Hospital Los Angeles Develops Liquid Biopsy Test for Pediatric Solid Tumors
CHLA researchers launched a liquid biopsy blood test to detect and differentiate between various pediatric cancers less invasively than a tissue biopsy.
A blood test could predict survival odds for patients with metastatic cancer
Measuring the amount of DNA that’s been shed by a tumor compared to the body’s typical amount of DNA may be a new tool to predict survival and guide treatment discussions for patients whose cancer has spread from the breast, prostate, lung or colon, a new study finds.
JNCCN Study Explores if Insurance is Keeping Pace with Trends in Targeted Cancer Therapy
New research from the University of California, San Francisco (USCF) and City of Hope in the July 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network examines coverage trends for circulating tumor DNA testing, also known as gene sequencing of ctDNA or “liquid biopsies.” The researchers found coverage rate rose from 0% to 38% in three years. The policies also increased in scope from 2017-2019, going from one cancer type to 12.
Biomarker test highly accurate in detecting early kidney cancer
A novel liquid biopsy method can detect kidney cancers with high accuracy, including small, localized tumors which are often curable but for which no early detection method exists, say scientists from Dana-Farber Cancer Institute.
The report in Nature Medicine suggests that if validated in larger trials and applied widely, the non-invasive test could find more early kidney cancers when they haven’t spread, thus reducing the mortality of the disease.
Researchers Announce Progress in Developing an Accurate, Noninvasive Urine Test For Prostate Cancer
Researchers at the Johns Hopkins Kimmel Cancer Center have made significant progress toward development of a simple, noninvasive liquid biopsy test that detects prostate cancer from RNA and other specific metabolic chemicals in the urine.